Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Behandling av moderat postoperativt tilbakefall ved Crohns sykdom: en randomisert kontrollert utprøving av terapeutisk eskalering, POMEROL-forsøket. (POMEROL) (POMEROL)

Study type : A 30 months, multicentre, open-label strategic randomized controlled trial

Population : Chron's Disease (CD) patients with an i2 endoscopic postoperative recurrence in the year following ileocolonic resection (6-12months after ileocolonic resection).

Treatments :

Stratification at inclusion according to prophylactic therapy.

Patients randomized in 2 arms:

  • Status quo arm: if the patient received no prophylactic therapy, no treatment will be started; if the patient received a prophylactic therapy, the same will be continued at the same dose.
  • Therapy escalation arm: infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.

Main objective : To evaluate the proportion of CD patients without endoscopic postoperative recurrence (i0-i1) at 12 months in the arm receiving therapy escalation compared to status quo arm in patients having an i2 endoscopic postoperative recurrence 6-12months after ileocolonic anastomosis with restoration of faecal stream.

Studieoversikt

Detaljert beskrivelse

Number of patients : 360 patients in approximatively 25 sites in France.

Recruitement period : The trial duration for each patients will be 12 months from radomization (18 to 24 months from screening (ie : post-operatively))

Endpoints:

Primary endpoints: Proportion of patients with an i0-i1 modified Rutgeerts score at 12 months.

Secondary endpoints:

  • Proportion of patients with an i3-i4 modified Rutgeerts score at 12 months

  • Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months

  • Proportion of patients with an i0 modified Rutgeerts score at 12 months

  • PRO2 score at 12 months

  • Clinical postoperative recurrence within 12 months: average daily SF ≥ 3.5 and average daily AP score ≥ 1.5, AND

    • increased CRP compared to inclusion, at least + 10 mg/l
    • OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g
  • Surgical recurrence within 12 months: need for a new ileocolonic resection

  • Endoscopic dilatation within 12 months: need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy

  • Time to clinical postoperative recurrence

  • Serious adverse events

  • Quality of life: EQ5D-5L questionnaire

  • Work productivity: Work Productivity and Activity Impairment questionnaire

Studietype

Intervensjonell

Registrering (Faktiske)

213

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Crohn's disease diagnosed according usual criteria
  • Bowel resection with ileocolonic anastomosis performed removing all inflammatory lesions
  • Postoperative endoscopy performed between 6 and 12 months after ileocolonic anastomosis reaching the neoterminal ileum (patients who underwent a two stage surgical procedure are also eligible if the endoscopic evaluation is performed 6-12 months after restoration of the fecal stream)
  • Moderate endoscopic postoperative recurrence classified i2 according to the Rutgeerts score at 6-12 months, validated by a blinded central reading

Exclusion Criteria:

  • Patients with an ostomy
  • Ulcerative colitis or IBD type unclassified
  • Ileorectal or ileal pouch-anal anastomosis
  • Symptoms defined as average daily SF ≥ 3.5 and average daily AP score ≥ 1.5 having started after a free interval without symptoms of at least one month after surgery
  • Patients with obstructive symptoms of CD defined by a CDOS > 4
  • Patients exposed to infliximab before index surgery with a primary non-response (no clinical effect after 2 infusions at the discretion of the treating gastroenterologist) or history of infusion reactions to infliximab or history of detectable anti-infliximab antibodies
  • Patients treated with biological therapy (except for intraocular injections) or an investigational medical product after index surgery
  • Patients having started thiopurines or methotrexate more than 6 weeks after ileocolonic anastomosis with restoration of the fecal stream
  • Patients in whom not all inflammatory lesions have been removed at index surgery
  • Patients with active perianal Crohn's disease
  • Patients with a contraindication to infliximab: cancer in the 5 years prior to inclusion excluding non-melanoma skin cancer, active tuberculosis or untreated latent tuberculosis, moderate or severe heart failure, HIV or HBV infection (serology < 6 months), recent live vaccination (within 4 weeks of baseline)
  • Pregnant women
  • Patients under legal protection or unable to express their consent.
  • Patients not affiliated to a health insurance system.
  • Patients deprived of liberty by judiciary or administrative decision or hospitalized without consent or admitted in a sanitary or social institution for another reason than research.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Status quo arm

If the patient received no prophylactic therapy after resection, no treatments will be started.

If the patient received a prophylactic therapy after resection, the same will be continued at the same dose.

Stratification 1 : No treatments

Stratification 2 : Immunosuppressors at same dose

Eksperimentell: Therapy escalation arm

Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.

Stratification 1: Infliximab-CT-P13

Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors

Andre navn:
  • Remsima

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of patients with an i0-i1 modified Rutgeerts score at 12 months.
Tidsramme: Month12

Number of patients with an i0-i1 modified Rutgeerts score at 12 months.

Month12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of patients with an i3-i4 modified Rutgeerts score at 12 months
Tidsramme: Month 12

Number of patients with an i3-i4 modified Rutgeerts score at 12 months

Month 12
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months
Tidsramme: Month 12

Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months

Month 12
Proportion of patients with an i0 modified Rutgeerts score at 12 months
Tidsramme: Month 12

Proportion of patients with an i0 modified Rutgeerts score at 12 months

Month 12
Patient Reporting Outcome score at 12 months.
Tidsramme: Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12

Patient Reporting Outcome score at 12 months will be assessed for the evaluation of disease activity (clinical remission).

Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12
Clinical postoperative recurrence
Tidsramme: Baseline, Month 4, Month 8, Month 12

Clinical postoperative recurrence within 12 months defined by : Average daily Stool Frequency ≥ 3.5 and average daily Abdominal Pain score ≥ 1.5, AND

  • increased CRP compared to inclusion, at least + 10 mg/l
  • OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g

Average daily Stool frequency, average daily Abdominal Pain score, CRP and Calprotectin feacal will be combined to report the clinical postoperative recurrence (this outcome is is expressed without units)

Baseline, Month 4, Month 8, Month 12
Surgical recurrence within 12 months
Tidsramme: Baseline, Month 4, Month 8, Month 12

Surgical recurrence within 12 months defined by need for a new ileocolonic resection. Proportion of surgical recurrence within 12 months

Baseline, Month 4, Month 8, Month 12
Endoscopic dilatation within 12 months
Tidsramme: Baseline, Month 4, Month 8, Month 12

Endoscopic dilatation within 12 months defined by a need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy Proportion of endoscopic dilatation within 12 months

Baseline, Month 4, Month 8, Month 12
Time to clinical postoperative recurrence will be assessed
Tidsramme: Baseline, Month 4, Month 8, Month 12

Time to clinical postoperative recurrence will be assessed

Baseline, Month 4, Month 8, Month 12
Serious adverse events
Tidsramme: Screening, Baseline, Month 4, Month 8, Month 12

Occurence of Serious Adverse Events

Screening, Baseline, Month 4, Month 8, Month 12
Quality of life: EQ5D-5L questionnaires
Tidsramme: Baseline, week 2, week 6, Month 4, Month 8, Month 12

Quality of life will be assessed with the EQ5D-5L questionnaire

Baseline, week 2, week 6, Month 4, Month 8, Month 12
Work productivity and activity impairement questionnaires
Tidsramme: Baseline, week 2, week 6, Month 4, Month 8, Month 12

Work productivity and activity impairement will be assessed with work productivity and activity impairement questionnaires

Baseline, week 2, week 6, Month 4, Month 8, Month 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

21. desember 2021

Primær fullføring (Faktiske)

15. oktober 2026

Studiet fullført (Faktiske)

15. oktober 2026

Datoer for studieregistrering

Først innsendt

18. august 2021

Først innsendt som oppfylte QC-kriteriene

28. september 2021

Først lagt ut (Faktiske)

11. oktober 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere